There are a lot of other end points in the 006 that are MRI related that may provide DMOAD evidence over a longer period than what 008 needed in a shorter timeframe with the synovial fluid. I wonder if this sort of evidence may suffice. Donna certainly did mention Bio Markers but as Tropy’s great work illustrates it is not specifically mentioned in the end points of the 006 trial design.
PAR Price at posting:
$2.65 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)